Skip to main content
SpringerLink
Log in

Urothelkarzinom

Urothelial carcinoma

  • Übersichten
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Verschiedene Arbeitsgruppen beschäftigen sich mit der WHO-Klassifikation aus dem Jahre 2004, die den ehemaligen Differenzierungsgrad G1, G2 und G3 aufhebt und für das nicht muskelinvasive Harnblasenkarzinom genetisch stabile Low-grade- von genetisch instabilen High-grade-Urothelkarzinomen unterteilt. Beim muskelinvasiven Harnblasenkarzinom sollte vorerst im Rahmen der radikalen Zystektomie die extendierte Lymphknotendissektion Standardverfahren bleiben.

Abstract

Various study groups are working on the WHO classification of 2004 which eliminates the previous grades of differentiation G1, G2, and G3 and classifies non-muscle-invasive bladder cancer into genetically stable low-grade and genetically unstable high-grade urothelial carcinomas. In muscle-invasive bladder cancer, extended lymph node dissection as part of radical cystectomy should remain the standard procedure for now.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Burger M, Stief CG, Zaak D (2009) Hexaminolevulinate is equal t 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology 74:1282–1286

    Article  PubMed  Google Scholar 

  2. Dalbagni G, Vora K, Kaag M et al (2009) Clinical outcome in a contemporary series of restaged patients with clinical T1bladder cancer. Eur Urol 56:903–910

    Article  PubMed  Google Scholar 

  3. Denzinger S, Fritsche HM, Otto W (2008) Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder sparing approach? Eur Urol 53:146–152

    Article  PubMed  Google Scholar 

  4. Fritsche HM, Burger M, Svatek RS et al (2010) Characteristics and outcomes of patients with clinical T1G3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol 57:300–309

    Article  PubMed  Google Scholar 

  5. Grossman B, Gomella L, Fradet Y et al (2007) A phase 3 multicenter comparison of hexaminolaevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 178:62–67

    Article  PubMed  Google Scholar 

  6. Herr HW (2008) Is maintenance Bacillus Calmette Guerin really necessary? Eur Urol 54:971–973

    Article  PubMed  Google Scholar 

  7. Malmström PU, Sylvester RJ, Crawford DE (2009) An individual patient data meta analysis of long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette Guerin for non-muscle invasive bladder cancer. Eur Urol 56:247–256

    Article  PubMed  Google Scholar 

  8. May M, Brookman-Amissah S, Roigas J et al (2010) Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organization classifications. Eur Urol 57:850–858

    Article  PubMed  Google Scholar 

  9. Roth B, Wissmeyer MP, Zehnder P (2010) A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. Eur Urol 57:205–211

    Article  PubMed  Google Scholar 

  10. Schumacher MC, Holmäng S, Davidsson T et al (2010) Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-amoinolaevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 57:293–299

    Article  PubMed  CAS  Google Scholar 

  11. Stenzl A, Penkoff H, Dajc-Sommerer E (2011) Detection and clinical outcome of urinary bladder cancer with 5 aminolaevulinic acid- induced fluorescence cystoscopy: a multicenter randomized, double-blind placebo-controlled trial. Cancer 117:938–947

    Article  PubMed  Google Scholar 

  12. Stenzl A, Penkoff H, Dajc-Sommerer E (2011) Detection and clinical outcome of urinary bladder cancer with 5 aminolaevulinic acid- induced fluorescence cystoscopy: a multicenter randomized, double-blind placebo-controlled trial. Cancer 117(5):938–947

    Article  PubMed  Google Scholar 

  13. Stenzl A, Burger M, Fradet Y (2010) Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 184:1907–1913

    Article  PubMed  Google Scholar 

  14. Tilki D, Svatek RS, Novara G et al (2010) Stage pT0 at radical cystectomy confers improved survival: an international study on 4430 patients. J Urol 184:2218

    Article  Google Scholar 

  15. Tilki D, Reich O, Karakiewicz PI et al (2010) Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion in patients treated with radical cystectomy. Eur Urol 58:112–117

    Article  PubMed  Google Scholar 

  16. Van Rhijn BWG, Zuiverloon TCM, Vis AN et al (2010) Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 58:433–441

    Article  Google Scholar 

  17. Chade DC, Shariat SF, Adany A et al (2010) Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol 184(2):454–459

    Google Scholar 

  18. Leissner J (2005) Lymphadenenctomy for bladder cancer. Diagnostic and prognostic significance as well as therapeutic benefit. Urologe A 44(6):638–644

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Urologie, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    H. Rübben  & F. vom Dorp

Authors
  1. H. Rübben
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. vom Dorp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Rübben .

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rübben , H., vom Dorp, F. Urothelkarzinom. Urologe 50 (Suppl 1), 176 (2011). https://doi.org/10.1007/s00120-011-2669-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s00120-011-2669-5

Schlüsselwörter

Keywords

Search

Navigation